PART I . The Company We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Our commercial products are: (i) ZTlido (lidocaine topical system) 1.8%, a ...
Q2 FY2026 — expected 2026-09-26
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-31 | 2024-12-31 | 0000950170-25-047800 | EDGAR | 160K words |
| 2024-03-12 | 2023-12-31 | 0000950170-24-029473 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0000950170-23-006493 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001213900-22-009229 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001213900-21-019230 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-283153 | EDGAR | 74K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108029 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071517 | EDGAR | — |
| 2025-01-17 | 2024-09-30 | 0000950170-25-006755 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096199 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058630 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063810 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041842 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0000950170-23-021743 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001213900-22-069366 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001213900-22-047404 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001213900-22-027064 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001193125-26-105675 | EDGAR | 1K words |
| 2026-03-13 | 0001193125-26-104940 | EDGAR | — |
| 2026-02-20 | 0001193125-26-061371 | EDGAR | — |
| 2026-02-03 | 0001193125-26-035833 | EDGAR | — |
| 2026-02-02 | 0001193125-26-033620 | EDGAR | — |
| 2025-12-30 | 0001193125-25-336947 | EDGAR | — |
| 2025-12-22 | 0001193125-25-328656 | EDGAR | — |
| 2025-12-17 | 0001193125-25-321928 | EDGAR | — |
| 2025-12-12 | 0001193125-25-317587 | EDGAR | — |
| 2025-12-11 | 0001193125-25-316239 | EDGAR | — |
195 total filings indexed. 168 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001820190 |
| Ticker | SCLX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.scilexholding.com |
| Listed | 2022-11-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report